Table 4.
Associations between baseline variables and irAEs.
| Parameter | P-value | Hazard Ratio | 95% Hazard Ratio Confidence Limits | |
|---|---|---|---|---|
| Year | 0.58 | 1.02 | 0.94 | 1.11 |
| Sex, Male vs. Female | 0.42 | 1.05 | 0.94 | 1.17 |
| Age group, year (ref=18–49) | ||||
| 50–64 | 0.18 | 1.23 | 0.91 | 1.65 |
| 65–74 | 0.11 | 1.28 | 0.95 | 1.72 |
| 75+ | 0.14 | 1.26 | 0.93 | 1.70 |
| Line of Treatment (ref=1st) | ||||
| 2nd + | <.0001 | 0.77 | 0.67 | 0.87 |
| Census Region (ref=Midwest) | ||||
| Northeast | 0.21 | 1.11 | 0.94 | 1.32 |
| South | 0.57 | 1.04 | 0.91 | 1.18 |
| West | 0.57 | 1.06 | 0.86 | 1.31 |
| Race (ref=White) | ||||
| Asian | 0.60 | 1.11 | 0.75 | 1.64 |
| Black | 0.16 | 1.13 | 0.95 | 1.35 |
| Hispanic | 0.03 | 1.30 | 1.03 | 1.65 |
| Unknown | 0.29 | 1.09 | 0.93 | 1.29 |
| I/O (ref=Atezolizumab) Nivolumab Pembrolizumab | ||||
| Nivolumab | 0.14 | 1.28 | 0.92 | 1.78 |
| Pembrolizumab | 0.42 | 1.15 | 0.82 | 1.63 |